ASCO 2016: Accuracy of multi-parametric MRI to predict further investigational biopsy

Bookmark and Share
Published: 6 Jun 2016
Views: 3727
Prof Nick James and Prof Charles Ryan

Prof Nick James (Warwick medical School Cancer Research, University of Warwick, UK) and Prof Charles Ryan (UCSF School of Medicine, San Francisco, USA) look at some of the ASCO highlights around the accuracy of multi-parametric MRI to predict which patients require further investigational biopsy.

They also discussed the Phase II IMAAGEN trial - Effect of abiraterone acetate and low-dose prednisone on prostate-specific antigen and radiographic disease progression in patients with non-metastatic castration-resistant prostate cancer.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).